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Abstract
Background: Some human cancers demonstrate cellular hierarchies in which tumor-initiating cancer stem cells
generate progeny cells with reduced tumorigenic potential. This cancer stem cell population is proposed to be a
source of therapy-resistant and recurrent disease. Ewing sarcoma family tumors (ESFT) are highly aggressive cancers
in which drug-resistant, relapsed disease remains a significant clinical problem. Recently, the cell surface protein
CD133 was identified as a putative marker of tumor-initiating cells in ESFT. We evaluated ESFT tumors and cell lines
to determine if high levels of CD133 are associated with drug resistance.
Methods: Expression of the CD133-encoding PROM1 gene was determined by RT-PCR in ESFT tumors and cell
lines. CD133 protein expression was assessed by western blot, FACS and/or immunostaining. Cell lines were FACS-
sorted into CD133+ and CD133- fractions and proliferation, colony formation in soft agar, and in vivo
tumorigenicity compared. Chemosensitivity was measured using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assays.
Results: PROM1 expression was either absent or extremely low in most tumors. However, PROM1 was highly over-
expressed in 4 of 48 cases. Two of the 4 patients with PROM1 over-expressing tumors rapidly succumbed to
primary drug-resistant disease and two are long-term, event-free survivors. The expression of PROM1 in ESFT cell
lines was similarly heterogeneous. The frequency of CD133+ cells ranged from 2-99% and, with one exception, no
differences in the chemoresistance or tumorigenicity of CD133+ and CD133- cell fractions were detected.
Importantly, however, the STA-ET-8.2 cell line was found to retain a cellular hierarchy in which relatively chemo-
resistant, tumorigenic CD133+ cells gave rise to relatively chemo-sensitive, less tumorigenic, CD133- progeny.
Conclusions: Up to 10% of ESFT express high levels of PROM1. In some tumors and cell lines the CD133+ fraction
is relatively more drug-resistant, while in others there is no apparent difference between CD133+ and CD133- cells.
These studies reveal heterogeneity in PROM1/CD133 expression in ESFT tumors and cell lines and confirm that high
levels of PROM1 expression are, in at least some cases, associated with chemo-resistant disease. Further studies are
required to elucidate the contribution of PROM1/CD133 expressing cells to therapeutic resistance in a large,
prospective cohort of primary ESFT.
Background
Ewing’s sarcoma family tumors (ESFT) are malignant
tumors of bone and soft tissue that occur predominantly
in adolescents and young adults. Histologically they
appear as small round blue cell tumors and, although
some tumors display evidence of neural differentiation,
they more commonly lack defining morphologic features
[1]. Genetically, ESFT are characterized by recurrent
chromosomal translocations that result in the creation
of fusion oncogenes, most commonly EWS-FLI1 or
EWS-ERG [1]. For patients who present with localized
tumors, aggressive multi-modal therapy results in 5-year
overall survival rates of over 70% [2]. However, for
patients who present with overt metastasis, who fail to
respond to induction chemotherapy, or who relapse, the
prognosis remains dismal.
In recent years putative tumor-initiating cancer stem
cells have been isolated from human tumors (reviewed
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in Ref. [3]). These cells exist as a minority population
within the tumor, possess the stem cell properties of
self-renewal and multi-lineage differentiation capacity
and are proposed to be the root cells from which
tumors are derived and maintained [4-10]. Importantly,
it has been shown that tumor-initiating cancer stem
cells may be more resistant to standard chemo- and
radiation-based therapies than bulk tumor cells [11-14].
In addition, although definitive proof of tumor-initiating
populations requires study of freshly isolated primary
tumor samples, the cellular hierarchy of tumorigenicity
is sometimes preserved in established cancer cell lines
[15].
Recently, it was reported that the cell surface glyco-
protein CD133 is a marker of tumor-initiating cells in
ESFT [16]. For the current study we evaluated expres-
sion of the CD133-encoding PROM1 gene in a large
panel of ESFT tumors and cell lines to determine if high
expression might be useful as a marker of drug resis-
tance in ESFT. Our data show that PROM1 expression
is usually extremely low in primary tumors. However,
we identified in a small subset of cases (4 of 48) in
which PROM1 was highly over-expressed. Two of 4
tumors with PROM1 over-expression were highly resis-
tant to primary chemotherapy and 2 were responsive.
Studies of ESFT cell lines also showed considerable het-
erogeneity in PROM1 expression and in the frequency
and chemosensitivity of CD133+ and CD133- cell frac-
tions. Importantly, however, in one cell line - STA-ET-
8.2 - CD133 expression was found to be associated with
enhanced tumorigenic potential and increased drug
resistance. Thus, in at least some ESFT tumors and cell
lines, CD133+ cells are relatively more resistant to ther-
apy than their CD133- counterparts. The potential uti-
lity of PROM1/CD133 as a marker of therapeutic
resistance in ESFT requires prospective evaluation in a
large cohort of newly diagnosed patients.
Methods
Cell Lines & Tumor Specimens
ESFT cell lines were maintained and passaged as cellular
monolayers in 10% fetal bovine serum-containing media
as described [17,18]. STA-ET-8.2 cells were obtained
from Children’s Cancer Research Institute, Vienna, Aus-
tria and the remainder of cell lines from Childrens Hos-
pital Los Angeles (CHLA), CA. Primary tumor sections
and RNA were obtained from the Children’s Oncology
Group (COG) Biorepository in Columbus, Ohio (Coop-
erative Human Tissue Network - CHTN) and the
CHLA tumor bank. All specimens were obtained in
compliance with HIPAA regulations and following pro-
tocol review by institutional review board. Informed
consent for use of tumor samples for research purposes
was obtained from each subject or subject’s guardian.
Flow Cytometry & Cell Sorting
Cultured cells were trypsinized and resuspended in FcR
Blocking Reagent (Miltenyi Biotec, Auburn, CA, USA)
with 0.5% bovine serum albumin (Sigma, St Louis, MO,
USA) in phosphate-buffered saline (PBS). Mouse anti-
human CD133/2-PE (Miltenyi) monoclonal antibody
was then added (1:11 dilution) and incubated for 15 min
at 4°C in the dark. After two washes, labeled cells were
analyzed by a FACScan flow cytometer (Becton Dickin-
son). A minimum of 10,000 events was collected and
acquired using CellQuest software (Becton Dickinson).
For flow-activated cell sorting (FACS), cells were stained
for CD133/2-PE and isolated on FACS Vantage or
FACS Aria instruments (BD Biosciences). Analysis was
done using the Flow-Jo program (Tree Star, Ashland,
OR). Positive and negative gates were determined using
IgG stained and unstained controls. Isolated cells were
then washed twice with PBS and plated under the same
conditions as unsorted cells. For cell lines with less than
20% CD133+ cells, FACS was preceded by magnetic
bead sorting (MACS) to first enrich for the CD133
population and thereby improve FACS efficiency. Cells
were labeled with primary CD133/1 antibody (mouse
IgG1, Miltenyi Biotec, 1 ul per million cells), magneti-
cally labeled with rat anti-mouse IgG1 Micro beads
(Miltenyi Biotec, 20 ul per 10 million cells) and sepa-
rated by MACS LS column (Miltenyi Biotec) according
to manufacturer’s instructions. Since MACS-separated
cells might be saturated with the antibody (CD133/1), it
is recommended by the manufacturer to use an alterna-
tive antibody recognizing the second epitope of CD133
(CD133/2) when performing subsequent analyses of cell
separation. Thus, we used CD133/2 in the FACS experi-
ment when evaluating sorting efficiency of MACS-sorted
cells.
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR)
Total RNA was extracted from cells and frozen tissue
sections using Qiagen columns (Qiagen, Valencia, CA).
First strand complementary DNA (cDNA) was synthe-
sized from 250-500 ng RNA using iScript Reverse Tran-
scriptase kit (Bio-Rad, Hercules, CA). Primers for
semi-quantitative RT-PCR were: PROM1 (CD133)
sense-GACCGACTGAGACCCAACAT and antisense-
TGGTTTGGCGTTGTACTCTG; GAPDH sense- CTT-
TAACTCTGGTAAAGTGG and antisense-TTTTGG-
CTCCCCCCTGCAAAT. Quantitative realtime RT-PCR
(Q-RT-PCR) was performed using a validated TaqMan
Gene Expression Assay (Applied Biosystems;
Hs01009261-m1) which detects both known isoforms of
PROM1. Assays were performed in triplicate on an
Applied Biosystems 7900HT system. Average Ct values
were normalized relative to expression of GAPDH and
Jiang et al. BMC Cancer 2010, 10:116
http://www.biomedcentral.com/1471-2407/10/116
Page 2 of 12
b -Actin in the same sample using the formula: % expres-
sion = 2-ΔCt × 100.
Western Blot
Whole cell lysates were analyzed by western blot using
standard procedures. Primary antibodies used were:
anti-CD133 (1:500)(Santa Cruz Biotech, Santa Cruz,
CA); anti- Bax (1:1000) (BD Pharmingen, San Jose, CA);
anti-Bcl-XL(1:200)(Santa Cruz Biotech, Santa Cruz, CA);
anti-Bcl2(1:200)(Santa Cruz Biotech, Santa Cruz, CA);
anti-survivin 1 (1: 1000)(Novus Biologicals, Littleton,
CO); anti-ABCG2 (1:500)(Abcam, Cambridge, MA) and
anti-b-actin (1:1000)(Santa Cruz Biotech, Santa Cruz,
CA). Immunostaining cells cultured on chamber slides
were rinsed in PBS and fixed in ice cold acetone for
5 min. For frozen tissue samples tumor tissue was fresh-
frozen in Tissue-Tek O.C.T. compound (Sakura Fine-
technical, Tokyo, Japan), cryosectioned at 10 um then
fixed in acetone for 10 min at -20°C. To detect CD133,
tumor sections and chamber slides were pre-incubated
with 10% normal Donkey serum, then hybridized with
anti-CD133 antibody (rabbit polyclonal IgG; 1: 200;
Abcam, Cambridge, MA) for 1 hour at room tempera-
ture. The primary antibodies were detected with Cy3
conjugated Donkey anti-rabbit IgG, (1: 500; Jackson
Immuno West Grove, PA). Sections were counterstained
with DAPI, viewed with a Leica DM RXA Upright
Fluorescence Microscope and photographed using a
SKY camera on the system (Applied Spectral Imaging,
Inc., Carlsbad, CA).
Cell Growth and Viability Assay
FACS-sorted cells were plated in triplicate wells at a
density of 3 × 104 cells/35 mm dish and total cell counts
and cell viability determined using a ViCell XR cell
counter (Beckman Coulter) on days 0, 1, 3, 5, 7 and 14.
Cell growth and viability following drug treatment was
assessed using the CellTiter-GIo Luminescent Cell Via-
bility Assay (Promega, Madison, MI). Cells were plated
at a density of 5 × 103 cells/well in 96 flat-bottomed
plates, allowed to attach overnight, and then chemother-
apeutic agents added at increasing concentrations. Survi-
val of cells was assessed 24-96 hrs post-treatment with
Doxorubicin, Etoposide and/or Vincristine as individual
agents or in combination. (Calbiochem, San Diego, CA).
Colony and Sphere Formation Assays
For soft agar colony formation assays cells were plated
as single cell suspensions in 0.35% noble agar as pre-
viously described [19]. Cells were maintained at 37°C in
a humidified incubator for 2-4 weeks and macroscopic
colony formation assessed. To assess sphere-forming
ability in serum and non-serum containing media in
nonadherent conditions, single FACS-sorted CD133+ or
CD133- cells were seeded into low attachment 96-well
plates. Visual inspection was performed the day after
the initial plating to confirm that each contained a sin-
gle cell. After 3-4 weeks, spheres that contained > 50
cells were counted.
Xenograft Assays
Nonobese diabetic (NOD)-severe combined immunode-
ficiency (SCID) mice (Charles River Laboratories) were
injected with 5 × 106 ESFT parent or CD133 FACS-
sorted cells. Tumor growth was monitored over time
and the frequency of tumor formation compared
between sorted and unsorted cells. Studies were carried
out with the assurance of the Institutional Animal Care
and Usage Committee.
Statistical Analysis
All assays were repeated at least 3 times and values in
the figures and text are reported as means ± SD. Statis-
tically significant differences (p.0.05) between mean
values was determined by Student’s t test.
Results
Increased expression of PROM1 and CD133+ cell
frequency in a subset of primary ESFT
CD133+ cells were shown to be extremely rare in a
study of 8 primary ESFT [16]. To define the relative
levels of expression of the CD133-encoding PROM1
gene in a larger cohort of ESFT we evaluated 48 tumor
RNA samples by quantitative RT-PCR. As shown, con-
sistent with a low frequency of CD133+ cells, PROM1
expression was extremely low relative to housekeeping
gene expression in most tumors (Fig 1A). In contrast,
however, the PROM1 transcript was readily amplified
from 11 tumors and in 4 tumors expression was at least
40-fold greater than the median (Fig 1A, cases marked
with arrows). Data were equivalent whether normalized
to GAPDH or b-Actin (not shown). Translocation and
tissue of origin data were available for 40 and 43 of the
48 tumors, respectively. As expected, the majority of
tumors expressed an EWS-FLI1 fusion; however, there
was a significant over-representation of EWS-ERG
fusions among the 11 PROM1 positive tumors (Fig 1B).
Notably, two of the four patients with PROM1 over-
expressing tumors had highly drug-resistant disease and
died 11 and 13 months from diagnosis (one with an
EWS-FLI1 and one with an EWS-ERG tumor; Fig 1A).
To determine if over-expression of the PROM1 tran-
script is indicative of an increased frequency of CD133+
cells we obtained fresh-frozen tumor sections from a
PROM1 negative and a PROM1 positive case. In keeping
with the relative levels of transcript expression, only
rare CD133+ cells were detected in the PROM1 low
case while large numbers of CD133+ cells were apparent
Jiang et al. BMC Cancer 2010, 10:116
http://www.biomedcentral.com/1471-2407/10/116
Page 3 of 12
in the PROM1 over-expressing tumor (Fig 1B). Signifi-
cantly, this PROM1-high, EWS-ERG+ bone tumor was
highly drug resistant and the level of PROM1 (data not
shown) and frequency of CD133+ cells increased further
following induction chemotherapy (Fig 1C) suggesting
that the CD133+ cells were relatively more chemo-resis-
tant than their CD133- counterparts (Fig 1B).
Together these data demonstrate that although CD133+
cells are usually infrequent in ESFT, in a subset of cases
large numbers of CD133+ cells can be identified. More-
over, this increased frequency of CD133+ cells is reflected
by increased expression of PROM1. Importantly, 2 of 4
PROM1 over-expressing tumors in this cohort were highly
resistant to induction chemotherapy suggesting that, in at
least some cases of primary ESFT, CD133 may be useful
as a marker of chemo-resistant disease.
CD133 expression in ESFT cell lines is highly variable and
cell line-specific
Although tumor-initiating cancer stem cells are defini-
tively isolated from primary tumors [20], some cancer
cell lines retain a cellular hierarchy thus permitting pro-
spective isolation of stem cell populations from cultured
cells [15]. To define the frequency of CD133+ cells in
ESFT cell lines we evaluated PROM1 and CD133
expression in 9 well-established lines by RT-PCR and
western blot, respectively. PROM1/CD133 expression
was found to be variable but high levels were detectable
Figure 1 PROM1 is highly expressed by some primary tumors. (A): PROM1 expression was assessed by quantitative RT-PCR in 48 primary ESFT
specimens. Levels of expression (normalized relative to GAPDH in the same sample) were < 1% in 37 tumors, 1-2% in 5 tumors, 2-3% in 2 tumors,
and > 3% in 4 tumors (marked with arrows). Median expression of all 48 tumors was 0.06%. Similar expression data were generated when Ct values
were normalized to expression of ACTIN instead of GAPDH (not shown). Two of 4 high-expressing cases demonstrated primary drug resistance
resulting in early death. NED: no evidence of disease at last follow-up; DOD: dead of disease. (B): Translocation and tissue of origin data for the 48
tumors evaluated in (A). EWS-ERG+ fusions were significantly over-represented among the 11 PROM1 expressing tumors (p = 0.01, Fisher’s exact
test). (C): Frozen tumor sections obtained from a PROM1-negative and a PROM1-over-expressing tumor (highest expressing tumor from (A)) were
stained for CD133. Only rare CD133+ cells were detected in the PROM1-negative tumor. In contrast, large numbers of CD133+ cells were detected
in the chemoresistant PROM1-over-expressing tumor and the number of CD133+ cells increased post-therapy.
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in two of six EWS-FLI1+ cell lines and in all three
EWS-ERG+ cell lines (Fig 2A). To establish if differing
levels of expression were due to overall differences
among all cells or a result of different frequencies of
CD133+ cells, we used immunostaining and flow cyto-
metry to directly assess the prevalence of CD133+ cells
in each culture. The antibody we used for these studies
is specific for the AC133 epitope of CD133 that is pre-
sent on progenitor cells [21]. First, immunocytochemical
staining revealed that while nearly all TC252 cells exhi-
bit dense cell surface expression of CD133, STA-ET-8.2
and A4573 display a heterogeneous mixture of CD133+
and CD133- cells (Fig 2B). These data are consistent
with the relative levels of overall CD133 transcript and
protein detected in the three cell lines (Fig 2A). Next,
we used flow cytometry to more precisely define the
proportion of CD133+ vs. CD133- cells. Interestingly,
although CD133+ cells were identified in all the cul-
tures, the frequency ranged from only 2% of A4573 cells
to nearly 100% of TC252 cells (Fig 2C). Together, these
data demonstrate that, like primary tumors, the fre-
quency of CD133+ cells in established ESFT cell lines
varies widely and that expression is, in general, higher in
EWS-ERG than EWS-FLI1 cells.
CD133+ STA-ET-8.2 cells display enhanced proliferation
in vitro
To establish if a CD133-defined cellular hierarchy exists
in ESFT cell lines we sorted four different lines into
CD133+ and CD133- fractions. Growth and morphology
of the sorted cells was monitored over time in several
independent experiments and differential expression of
CD133 expression in the sorted populations was con-
firmed at the start and end of each experiment by RT-
PCR and/or flow cytometry (not shown). Intriguingly,
although there was no difference in growth rate or mor-
phologic appearance between CD133+ and CD133- cells
in A4573, TC71 or 5838 cell lines (Fig 3A), CD133+
STA-ET-8.2 cells consistently grew faster than their
CD133- counterparts (Fig 3B). In addition, we observed
a marked change in cellular morphology between
CD133+ cells and CD133- cells. Whereas CD133- cells
grew as uniform, evenly distributed adherent mono-
layers, CD133+ STA-ET-8.2 cells preferentially grew in
aggregate clusters of cells (Fig 3C). Together these data
suggested that CD133+ STA-ET-8.2 cells might be
enriched for tumor-initiating cancer stem cells.
CD133+ STA-ET-8.2 cells form tumor spheres and produce
CD133+ and CD133- progeny
Prior studies have shown that CD133+ tumor-initiating
cells uniquely form and can be expanded as 3-dimen-
sional spheres in non-adherent culture conditions [5,22].
Therefore, we compared sphere-forming capacity of
CD133+ and CD133- STA-ET-8.2 cells in vitro. Single
CD133+ or CD133- cells were independently seeded
into ultra low adhesion 96-well plates that favor the pro-
liferation of undifferentiated cells. The number of
spheres was scored after 3-4 weeks in culture. Impor-
tantly, we observed that the ability of CD133+ cells to
generate and proliferate as tumor spheres was 5-fold
greater than CD133- cells. Multi-cellular spheres
Figure 2 CD133 expression in ESFT cell lines is highly variable. (A): Expression of CD133 in nine ESFT cell lines was examined by RT-PCR
and western blot analysis. The variability of protein expression in ESFT cell lines correlates with transcript expression. (B): Immunofluorescent
staining of CD133 in three ESFT cell lines shows wide variation in the frequency of CD133+ cells. (C): Flow cytometric analysis of ESFT cell lines
confirms widely variable frequencies of CD133+ cells in established cultures. Primary FACS plots are shown in the left panel and summary data
from three independent experiments is shown in the right panel for eight different ESFT cell lines.
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consisting of 500 to 3000 cells (Fig 4A; top panel) grew
from 11.4% of individually seeded CD133+ cells. In con-
trast, spheres were generated from only 2.3% of the sin-
gle-sorted CD133- cells (Fig 4A). Similar results were
seen whether cells were sorted into serum-containing or
defined bFGF/EGF neurosphere media (not shown).
Importantly, consistent with proliferation assays, we
observed no difference in sphere-formation ability
between CD133+ and CD133- TC71 cells (not shown).
In normal and malignant neural differentiation, CD133+
stem cells undergo asymmetric cell division to generate
both CD133+ and CD133- progeny [5]. To determine if
CD133+ STA-ET-8.2 cells are similarly capable of gener-
ating both CD133+ and CD133- daughter cells we evalu-
ated clonally derived spheres generated from single
CD133+ cells. Individual spheres derived from CD133+
cells were expanded in culture for several passages and
then progeny analyzed by flow cytometry. As shown in
Fig 4B, CD133+ cell-derived spheres contained both
CD133+ and CD133- cells. Thus, these data support the
hypothesis that the heterogeneity of CD133 expression in
STA-ET-8.2 cell cultures is consequence of asymmetric
cell division in which CD133+ cells give rise to both
CD133+ and CD133- daughter cells.
CD133+ STA-ET-8.2 cells preferentially form colonies in
soft agar and tumors in immune deficient mice
By definition cancer stem cells possess tumor-initiating
capability [20]. To assess whether CD133+ ESFT cells
display enhanced anchorage-independent growth
in vitro we performed soft agar assays of FACS-sorted
CD133+ and CD133- cells. In keeping with their differ-
ential growth characteristics in adherent culture, CD133+
STA-ET-8.2 cells displayed dramatically enhanced
growth in anchorage-independent conditions compared
to CD133- STA-ET-8.2 cells (Fig 5A). In contrast to
STA-ET-8.2 cells, and consistent with findings in
adherent culture, no differences in colony formation
were observed between CD133+ and CD133- cells
derived from parental TC71, A4573 or 5838 cell lines
(Fig 5A and data not shown). Thus, among the four
ESFT cell lines tested, the enhanced clonogenic capacity
of CD133+ cells in anchorage-independent conditions
was unique to STA-ET-8.2 cells.
Next, we assessed whether increased capacity to gener-
ate colonies in soft-agar was associated with increased
tumorigenicity in vivo. Cells were FACS-sorted into
CD133+ and CD133- populations, expanded in culture as
independent populations for three to five passages and
Figure 3 CD133+ STA-ET-8.2 cells show enhanced growth characteristics. (A): Direct cell counting of CD133+ and CD133- from A4573, 5838
and TC71 cultures shows no difference in growth rate between CD133+ and CD133- populations. (B): In contrast to the cell lines shown in (A),
CD133+ STA-ET-8.2 cells grow faster than their CD133- counterparts. Data presented are mean ± s.d. of three independent experiments. (C):
Differential expression of CD133 is confirmed in FACS-sorted STA-ET-8.2 cells (left panel). CD133+ and CD133- cells show different growth
patterns with CD133+ cells demonstrating preferential growth in aggregate cell clusters, whereas CD133- cells grow as cellular monolayers (right
panel).
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then equal numbers of cells injected subcutaneously into
NOD-SCID mice. Significant enrichment of CD133+
cells and CD133- cells in the respective sorted popula-
tions was confirmed immediately prior to cell injection
(purity > 90%; Fig 5B). While 4 of 12 mice injected with
CD133+ STA-ET-8.2 cells developed a tumor, none of
the CD133- cell injections resulted in tumor formation
(Fig 5C). Xenograft tumors derived from CD133+ STA-
ET-8.2 cells displayed the classic poorly differentiated,
homogenous small round blue cell phenotype of ESFT
(Fig 5C; right panel). Immunostaining of these xenografts
further revealed that the tumors derived from CD133+
cells contained both CD133+ and CD133- cells and the
proportion of CD133- cells was significantly greater than
the ~7% of contaminating CD133- cells that were present
in the tumor cell inoculation (Fig 5C; right panel). In
contrast, no differences in tumorigenicity were observed
between CD133+ and CD133- TC71 cells: all mice
rapidly developed tumors (not shown). Together these
data provide preliminary in vivo evidence that the tumor-
initiating potential of CD133+ STA-ET-8.2 is greater
than that of CD133- cells and that CD133+ tumor-initiat-
ing cells undergo asymmetric cell division during tumor
growth to generate both CD133+ and CD133- progeny.
Serial dilution and serial transplantation experiments will
be required to define the precise frequency of tumori-
genic cells in each of these respective cell populations.
Finally, although the tumorigenicity of CD133+ STA-
ET-8.2 cells was enhanced compared to CD133- cells,
their capacity to initiate tumors was significantly less
than that of unsorted parent cells (Fig 5C). Specifically,
although tumors rapidly grew in 9 of 9 mice injected
with unsorted STA-ET-8.2 cells, only 4 of 12 mice
injected with the same number of CD133+ enriched
cells developed a tumor (Fig 5C). This unexpected
observation led us to hypothesize that either the CD133-
cells contribute to the inherent tumorigenicity of the
unsorted, parental cell line or that the process of FACS-
sorting had diminished the relative tumorigenic capacity
of all cells. To address this CD133+ and CD133-
STA-ET-8.2 cells were collected and injected together.
Despite the presence of a 50/50 mix of CD133+ and
CD133- cells (which is the homeostatic state of parental,
unsorted STA-ET-8.2 cells), no tumors formed in any of
the six mice that received this merged cell injection (Fig
5C). These data suggest that the process of FACS-sort-
ing negatively affects the tumor-initiating capacity of
STA-ET-8.2 cells irrespective of CD133 expression.
Whether MACS-sorting similarly affects the tumor-initi-
ating potential of these cells remains to be evaluated.
Figure 4 FACS-sorted CD133+ STA-ET-8.2 cells from spheres in non-adherent culture conditions. (A): STA-ET-8.2 cells were isolated by
FACS using anti-CD133 antibody followed by plating at single cell dilution in 96 well plates. After 3-4 weeks in culture, individual spheres of
> 50 cells (top image) were apparent in 11.4% of wells seed with a single CD133+ cell whereas sphere-forming efficiency from CD133- cells was
only 2.3%. Results are the sum of 2 independent experiments using 192 wells/experiment. (B): Four individual CD133+ cell-derived spheres from
(A) were collected and analyzed by flow cytometry. As shown, the percentage of CD133+ cells in the spheres ranged from 54-86% indicating
that colonies derived from individual CD133+ STA-ET-8.2 cells contain both CD133+ and CD133- cells.
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Figure 5 CD133+ STA-ET-8.2 cells are more tumorigenic than CD133- cells. (A): CD133+ STA-ET-8.2 cells readily form colonies in soft agar
while CD133- STA-ET-8.2 cells form significantly fewer colonies. In contrast, no difference in colony formation is seen in FACS-sorted TC71 cells.
Images are representative of 6 wells/experiment from 3 separate experiments. (B): Analysis of CD133 expression in FACS-sorted cells prior to
injection confirms significant enrichment of CD133+ cells in CD133+ fraction. (C): Variable tumorigenicity of sorted and unsorted STA-ET-8.2 cells
is demonstrated by xenograft assays (left panel). In particular, unsorted STA-ET-8.2 cells reliably form tumors in NOD-SCID mice whereas cells that
have been FACS-sorted are highly inefficient. Among sorted populations, only CD133+ cells generated tumors. CD133+ cell-derived xenografts
demonstrate the classic small round blue cell ESFT phenotype and contain both CD133+ and CD133- cells (right panel).
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CD133+ STA-ET-8.2 cells are more resistant to
chemotherapeutic drugs
Cancer stem cells have been reported to be more resis-
tant to chemotherapy [11,23]. We therefore examined
the viability of sorted CD133+ and CD133- STA-ET-8.2
cells that were exposed to increasing doses of doxorubi-
cin, etoposide and vincristine alone or in combination
for 24-96 hours. As shown (Fig 6A-D), both CD133+
and CD133- STA-ET-8.2 cells displayed a dose-depen-
dent sensitivity to these chemotherapeutic agents.
However, the relative resistance of CD133+ cells to
drug-induced cell death was significantly greater than
for CD133- cells at all three doses (Fig 6A). In contrast,
no difference in cell viability was seen between CD133+
and CD133- populations sorted from TC71 (Fig 6E),
A4573 or 5838 cell lines (data not shown). Thus, these
data demonstrate that CD133 expression enriches for
chemo-resistant cells in the STA-ET-8.2 cell line but
not in the other ESFT cell lines tested.
Having established that CD133+ STA-ET-8.2 cells dis-
play greater drug resistance than autologous CD133-
cells, we next sought to investigate the mechanism of
this differential sensitivity. FACS-sorted populations
were evaluated by western blot for relative expression of
proteins involved in apoptosis and multi-drug resistance.
No differences between CD133+ and CD133- STA-ET-
8.2 cells were observed in the expression of BH3-pro-
teins (Bcl-2, Bcl-XL, Bax), survivin, or the ATP-binding
cassette protein ABCG2 (Fig 6F). Similarly, equivalent
levels of P-glycoprotein and activated AKT were
detected in the sorted and unsorted cells (not shown).
Thus, as with many putative cancer stem cells [21], the
mechanism of enhanced chemo-resistance in CD133+
STA-ET-8.2 cells remains to be elucidated.
Discussion
The pentaspan transmembrane glycoprotein CD133, also
known as Prominin-1, was originally described as a
hematopoietic stem cell marker [24] and subsequently
shown to be expressed by a number of progenitor cells,
including those of the epithelium where it is expressed
on the apical surface [25]. Since the discovery of CD133
+ brain tumor stem cells [5], CD133 has been used as a
marker for purifying cancer stem cells in other solid
tumors, including liver [26], pancreas [27], melanoma
[28], prostate [8] and colon [29]. Significantly, a recent
study of 8 primary ESFT reported the frequency of
CD133+ tumor cells to be 4-8% and functional studies
further implicated these cells as putative tumor-initiat-
ing cancer stem cells [16].
We evaluated expression of the CD133-encoding gene
PROM1 in a large cohort of primary ESFT. Consistent
with an overall low frequency of CD133+ cells, we
found PROM1 expression to be extremely low in most
cases of ESFT. The absence of detection of PROM1
transcript in 5 tumors may be indicative of true negative
status or, more likely, a reflection of the RNA having
been isolated from very small, closed needle biopsy spe-
cimens. Despite the generally low levels of PROM1
detection in primary tumors, however, in a significant
minority of cases (11 of 48) the transcript was readily
detected. Intriguingly, EWS-ERG fusion positive cases
were significantly over-represented among PROM1
expressing tumors. This was corroborated by in vitro
studies, which also revealed levels of PROM1/CD133 to
be, in general, higher in EWS-ERG than EWS-FLI1 cell
lines. Whether this difference between tumors with dif-
ferent fusion types is a function of differential effects of
the ETS fusion partner or a reflection of different cellu-
lar origins of EWS-FLI1 and EWS-ERG tumors is an
intriguing question that will require further study.
Significantly, in two cases (one EWS-FLI1 and one
EWS-ERG), high levels of PROM1 expression were asso-
ciated with primary drug-resistant disease. Moreover, in
one of these cases the frequency of CD133+ cells
increased post-treatment suggesting that the CD133+
fraction contributed to treatment failure. In contrast,
however, two other tumors with high levels of PROM1
responded well to standard therapy and both patients
are long-term, event-free survivors. Unfortunately, fro-
zen tissue was only available for one of the four
PROM1-high cases so it is not known if high PROM1
levels in the other cases were also associated with high
levels of glycosylated CD133. It may be that high levels
of PROM1 are predictive of chemoresistant ESFT but
only when accompanied by high expression of the glyco-
sylated CD133 protein. Studies designed to simulta-
neously evaluate transcript expression levels as well as
glycosylated and non-glycosylated CD133 protein
expression in fresh frozen ESFT specimens are necessary
to address this issue. Thus, expression of PROM1 in
ESFT is highly variable and the potential clinical signifi-
cance of high level PROM1 transcript expression
requires further evaluation in large, prospective studies.
The existence of discrete populations of tumor-initiat-
ing cells within established cultures indicates that even
cell lines that have been maintained for many years in
culture can retain cellular hierarchies in which tumori-
genic stem cells give rise to less tumorigenic progeny
[15,30-32]. Functional studies of CD133+ and CD133-
fractions derived from ESFT cell lines demonstrated sig-
nificant heterogeneity in their biologic properties. Speci-
fically, although CD133+ cells could be isolated from all
ESFT cell lines, only CD133+ cells isolated from the
STA-ET-8.2 cell line displayed evidence of stem cell
characteristics and chemo-resistance. In contrast, we
could discern no phenotypic or functional differences
between CD133+ and CD133- cells derived from other
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Figure 6 CD133+ cells are more resistant to chemotherapeutic agents. STA-ET-8.2 cells were FACS-sorted and CD133+ and CD133- fractions
treated with increasing concentrations of (A) Doxorubicin (Doxo), (B) Etoposide (Etop), (C) Vincristine (Vinc) or (D) a combination of all three
drugs at high (Doxo 10 μM; Etop 10 ug/ml; Vinc 100 ng/ml), medium (Doxo 2.5 μM; 20 Etop 2.5 ug/ml; Vinc 25 ng/ml) and low (Doxo 0.5 μM;
Etop 0.5 ug/ml; Vinc5 ng/ml) concentrations. Viability was assessed by MTS assay after 96 hrs (*p < 0.05) and CD133+ cells displayed increased
drug resistance. (E): CD133+ and CD133- TC-71 cells are equally sensitive to Doxo, Etop, and Vinc. (F): Western blot reveals no difference in
apoptosis and drug resistance protein expression between unsorted and CD133-sorted STA-ET-8.2 cell fractions.
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ESFT cell lines. Whether this inconsistency is a result of
genetic evolution in vitro or a true reflection of variable
significance of CD133 expression in the original tumors
remains to be determined.
Importantly, recent studies have challenged the uti-
lity of CD133 as a single marker of tumor-initiating
cell populations. CD133- tumor cells derived from
some primary tumors and cell lines possess self-
renewal and tumor-initiating potential even when
injected at very low numbers [22,32-34]. These con-
flicting data, when combined with the uncertain biolo-
gical role of CD133, highlight the need for additional
distinguishing markers that are directly involved in
maintaining the functional properties of the putative
cancer stem cell population [35]. Indeed, the variability
in PROM1 expression in primary ESFT combined with
the inconsistent biologic properties of CD133+ ESFT
cells in culture suggest that CD133 expression alone
will be insufficient to isolate drug-resistant cancer
stem cells in ESFT. Nevertheless, our data indicate that
PROM1/CD133 expression may be a useful marker of
increased chemoresistance in at least some cases of
primary ESFT and that the STA-ET-8.2 cell line will
be a useful tool to study the biology of these cells in
the laboratory.
Conclusions
Drug-resistant disease at diagnosis or at relapse remains
a major cause of mortality among patients diagnosed
with ESFT. An improved understanding of the mechan-
isms of drug-resistance and biomarkers that can pro-
spectively identify resistant tumors are desperately
needed. Our studies indicate that in some cases of ESFT
over-expression of the PROM1 transcript is associated
with primary drug-resistant disease. Future studies of
prospectively acquired primary tumors are now required
to definitively address the clinical significance of
PROM1 expression and its relationship to drug-resistant
CD133+ cells in ESFT.
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